RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
RETA
Delisted
RETA was delisted on the 25th of September, 2023.
149 hedge funds and large institutions have $884M invested in Reata Pharmaceuticals, Inc. Class A Common Stock in 2022 Q1 according to their latest regulatory filings, with 34 funds opening new positions, 40 increasing their positions, 50 reducing their positions, and 34 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
149
Holders Change
-2
Holders Change %
-1.32%
% of All Funds
2.36%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.03%
New
34
Increased
40
Reduced
50
Closed
34
Calls
$21.3M
Puts
$70.1M
Net Calls
-$48.8M
Net Calls Change
-$54M
Top Buyers
Top Sellers
| 1 |
Invesco
Atlanta,
Georgia
|
$1.84M |
| 2 |
Goldman Sachs
New York
|
$3.52M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
$18.4M |
| 4 |
Millennium Management
New York
|
$7.82M |
| 5 |
DFO
Duquesne Family Office
New York
|
$1.93M |
